Fryer Jeffrey M 的 Form 4 申報
Rallybio CorpRLYB，2022/1/11 申報
- 申報編號
- 0000899243-22-001629
- 申報時間
- 2022/1/11
- 交易日
- 2021/7/28-2022/1/7
- 申報延遲
- 167 天遲報
- 10b5-1 計畫
- 表單沒有這欄（2023 年以前）
這份申報列了 6 筆非衍生性交易、8 筆衍生性交易。公開市場買進合計 $9.41 萬。交易後 167 天才申報，超過 2 個營業日的期限。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Fryer Jeffrey MCIK 0001872879 | 高階主管（見申報備註） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/7/28 | Common Stock | J其他取得 | +32,648 | –F1 | – | 32,648 | 間接 | |
| 2021/7/28 | Common Stock | J其他取得 | +272,609 | –F1 | – | 272,609 | 間接 | |
| 2021/7/28 | Common Stock | J其他取得 | +201,934 | –F1 | – | 201,934 | 間接 | |
| 2021/7/28 | Common Stock | J其他取得 | +201,934 | –F1 | – | 201,934 | 間接 | |
| 2022/1/7 | Common Stock | P買進取得 | +705 | $8.97F6 | +$6,323.85 | 33,353 | 間接 | |
| 2022/1/7 | Common Stock | P買進取得 | +9,295 | $9.44F7 | +$87,744.8 | 42,648 | 間接 |
衍生性證券（表 II）
選擇權、認股權證、限制型股票單位等。股數是標的股票的股數；單價與金額是衍生證券本身的價格，交易後持有是衍生證券的單位數。
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2021/7/28 | Common Stock | J其他處分 | −272,609 | –F1 | – | 0 | 間接 | |
| 2021/7/28 | Common Stock | J其他處分 | −190,156 | –F1 | – | 0 | 間接 | |
| 2021/7/28 | Common Stock | J其他處分 | −190,156 | –F1 | – | 0 | 間接 | |
| 2021/7/28 | Common Stock | J其他處分 | −11,778 | –F1 | – | 0 | 間接 | |
| 2021/7/28 | Common Stock | J其他處分 | −11,778 | –F1 | – | 0 | 間接 | |
| 2021/7/28 | Common Stock | J其他處分 | −15,704 | –F1 | – | 0 | 間接 | |
| 2021/7/28 | Common Stock | J其他處分 | −16,944 | –F1 | – | 0 | 間接 | |
| 2021/7/28 | Common Stock | A公司授予取得 | +160,000 | $0.00 | $0 | 160,000 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation.
表 I 有 4 筆、表 II 有 7 筆交易的價格引用這則附註。
- F6
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.01 to $9.00, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (6) and (7) to this Form 4.
表 I 有 1 筆交易的價格引用這則附註。
- F7
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.01 to $10.00, inclusive.
表 I 有 1 筆交易的價格引用這則附註。
備註
Chief Financial Officer & Treasurer